Literature DB >> 11769299

A practice-based approach for converting from proton pump inhibitors to less costly therapy.

L M Lucas1, M S Gerrity, T Anderson.   

Abstract

CONTEXT: Projected cost for lansoprazole, the formulary proton pump inhibitor (PPI) at our institution, was $1.8 million in 1999. While some patients require PPI therapy, many could control their symptoms with a histamine H2-receptor antagonist blocker (H2 blocker) at a much lower cost.
OBJECTIVE: To evaluate a practice-based approach to converting patients from PPIs to H2 blockers.
DESIGN: Before-after study.
SETTING: Portland Veterans Affairs Primary Care Clinics. INTERVENTION: We developed guidelines and educated clinicians about the use of PPIs and H2 blockers. To help physicians convert appropriate patients from PPIs to H2 blockers, we gave them a list of their patients receiving PPIs, form letters for patients explaining the conversion, and structured prescription forms. Patient lists and e-mail reminders, as well as feedback on institutional performance, were sent to clinicians during the intervention period. OUTCOME MEASURES: Number of PPI and H2 prescriptions per enrollee and pharmacy costs.
RESULTS: The average number of PPI prescriptions per enrollee at our institution decreased from 0.39 in the 9 months before the intervention to 0.27 in the 9 months after the intervention. The associated pharmacy costs decreased from an average of $43 to $28 per enrollee per quarter, a difference of $15 or a savings of $80,000 per quarter. Accounting for the decrease in medication prices during the study, this difference was $11 per patient per quarter, corresponding to a savings of about $60,000 per quarter. With respect to the conversion process, more than 70% of clinicians felt the intervention had a big impact on how they prescribed PPIs and H2 blockers. Eighty-two percent of clinicians converted patients from PPIs to H2 blockers during clinic time; 56% did so during administrative time. Overall, more clinicians considered the intervention to be helpful rather than a hassle.
CONCLUSIONS: The number of PPI prescriptions decreased during the intervention and was sustained at least three quarters afterward. This low-intensity, practice-based intervention may serve as a model for other health care systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769299

Source DB:  PubMed          Journal:  Eff Clin Pract        ISSN: 1099-8128


  7 in total

1.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

2.  An automated tool for detecting medication overuse based on the electronic health records.

Authors:  Hojjat Salmasian; Daniel E Freedberg; Julian A Abrams; Carol Friedman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-12-12       Impact factor: 2.890

3.  Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies.

Authors:  Robert MacLaren; Tyree H Kiser; Rose Jung; Douglas N Fish
Journal:  P T       Date:  2006-12

4.  Prevalence of anti-ulcer drug use in a Chinese cohort.

Authors:  Tzeng-Ji Chen; Li-Fang Chou; Shinn-Jang Hwang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic: Quality Improvement Project.

Authors:  Naren Nallapeta; Jessica L Reynolds; Smita Bakhai
Journal:  J Clin Gastroenterol       Date:  2020 Nov/Dec       Impact factor: 3.174

6.  Identifying Risk Factors Associated with Inappropriate Use of Acid Suppressive Therapy at a Community Hospital.

Authors:  Amandeep Singh; Vijay Bodukam; Kirit Saigal; Jaya Bahl; Yvette Wang; Alexandra Hanlon; Yinghui Lu; Michael Davis
Journal:  Gastroenterol Res Pract       Date:  2016-10-12       Impact factor: 2.260

7.  Who has the guts to deprescribe proton pump inhibitors? A pharmacist-led intervention in a long-term care facility setting.

Authors:  Rachel Tandun; Carolyn Bubbar; Aaron M Tejani
Journal:  Aging Med (Milton)       Date:  2019-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.